Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
Humans
Aged
Peritoneum
/ pathology
Peritoneal Neoplasms
/ secondary
Hyperthermic Intraperitoneal Chemotherapy
Cytoreduction Surgical Procedures
Colorectal Neoplasms
/ pathology
Combined Modality Therapy
Ireland
/ epidemiology
Percutaneous Coronary Intervention
Hyperthermia, Induced
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Survival Rate
Registries
United Kingdom
/ epidemiology
Retrospective Studies
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
15
08
2022
accepted:
18
10
2022
revised:
11
10
2022
pubmed:
9
11
2022
medline:
10
1
2023
entrez:
8
11
2022
Statut:
ppublish
Résumé
The management of colorectal peritoneal metastases continues to be a challenge but recent evidence suggests cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve survival. Uncertainty about the relationship between age and tumour biology makes patient selection challenging particularly when reported procedure related morbidity is high and impact on survival outcomes unknown. The UK and Ireland Colorectal Peritoneal Metastases Registry was reviewed to assess the influence of age on efficacy of CRS and HIPEC. A review of outcomes from the UK and Ireland Colorectal Peritoneal Metastases Registry was performed. Data from 2000 to 2021 were included from five centres in the UK and Ireland, and the cohort were sub-divided into three age groups; <45 years, 45-65 years and >65 years old. Primarily, we examined post-operative morbidity and survival outcomes across the three age groups. In addition, we examined the impact that the completeness of cytoreduction, nodal status, or adverse pathological features had on long-term survival. During the study period, 1138 CPM patients underwent CRS HIPEC. 202 patients(17.8%) were <45 years, 549 patients(48.2%) aged 45-65 years and 387 patients(34%) >65 years. Overall, median length of surgery (CRS and HIPEC), median PCI score and rate of HIPEC administration was similar in all three groups, as was overall rates of major morbidity and/or mortality. Complete cytoreduction rates (CC0) were similar across the three cohorts; 77%, 80.6% and 81%, respectively. Median overall survival for all patients was 38 months following complete cytoreduction. Age did not appear to influence morbidity or long-term survival following CRS and HIPEC. When complete cytoreduction is achieved survival outcomes are good. The addition of HIPEC can be performed safely and may reduce local recurrence within the peritoneum.
Sections du résumé
BACKGROUND
The management of colorectal peritoneal metastases continues to be a challenge but recent evidence suggests cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve survival. Uncertainty about the relationship between age and tumour biology makes patient selection challenging particularly when reported procedure related morbidity is high and impact on survival outcomes unknown. The UK and Ireland Colorectal Peritoneal Metastases Registry was reviewed to assess the influence of age on efficacy of CRS and HIPEC.
METHODS
A review of outcomes from the UK and Ireland Colorectal Peritoneal Metastases Registry was performed. Data from 2000 to 2021 were included from five centres in the UK and Ireland, and the cohort were sub-divided into three age groups; <45 years, 45-65 years and >65 years old. Primarily, we examined post-operative morbidity and survival outcomes across the three age groups. In addition, we examined the impact that the completeness of cytoreduction, nodal status, or adverse pathological features had on long-term survival.
RESULTS
During the study period, 1138 CPM patients underwent CRS HIPEC. 202 patients(17.8%) were <45 years, 549 patients(48.2%) aged 45-65 years and 387 patients(34%) >65 years. Overall, median length of surgery (CRS and HIPEC), median PCI score and rate of HIPEC administration was similar in all three groups, as was overall rates of major morbidity and/or mortality. Complete cytoreduction rates (CC0) were similar across the three cohorts; 77%, 80.6% and 81%, respectively. Median overall survival for all patients was 38 months following complete cytoreduction.
CONCLUSION
Age did not appear to influence morbidity or long-term survival following CRS and HIPEC. When complete cytoreduction is achieved survival outcomes are good. The addition of HIPEC can be performed safely and may reduce local recurrence within the peritoneum.
Identifiants
pubmed: 36347966
doi: 10.1038/s41416-022-02037-5
pii: 10.1038/s41416-022-02037-5
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
42-47Investigateurs
Ronan Cahill
(R)
Faraz Khan
(F)
Edward Murphy
(E)
Sanjeev Dayal
(S)
Connor Shields
(C)
Alexios Tzivanakis
(A)
Jonathan Wild
(J)
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Dietz MV, van Kooten JP, Said I, Brandt-Kerkhof ARM, Verhoef C, Bremers AJA, et al. Survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma. Ann Surg Oncol. 2022; 29:6566–76.
Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19.
doi: 10.1016/S1470-2045(16)30500-9
Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3:585–94.
doi: 10.1002/bjs5.50179
Lundy ME, Moaven O, Perry KC, Mangieri CW, Valenzuela CD, Russell GB, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of colorectal cancer with peritoneal dissemination: 30 years of experience at a single institution. J Am Coll Surg. 2022;234:546–56.
doi: 10.1097/XCS.0000000000000091
Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110:779–85.
doi: 10.1002/jso.23728
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.
doi: 10.1200/JCO.2008.19.7160
Maggiori L, Elias D. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol. 2010;36:599–603.
doi: 10.1016/j.ejso.2010.05.007
Davis CH, Alexander HR Jr. What is the Current role of hyperthermic intraperitoneal chemotherapy in colorectal cancer? Adv Surg. 2021;55:159–74.
doi: 10.1016/j.yasu.2021.05.012
Spiegelberg J, Neeff H, Holzner P, Runkel M, Fichtner-Feigl S, Glatz T. Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer. World J Gastrointest Oncol. 2020;12:903–17.
doi: 10.4251/wjgo.v12.i8.903
Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256–66.
doi: 10.1016/S1470-2045(20)30599-4
Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13:109–31.
doi: 10.1002/1878-0261.12417
Gagniere J, Veziant J, Pereira B, Pezet D, Le Roy B, Slim K. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the elderly: is it reasonable? A meta-analysis. Ann Surg Oncol. 2018;25:709–19.
doi: 10.1245/s10434-017-6313-5
Ezzedine W, Mege D, Aubert M, Duclos J, Le Huu Nho R, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for resectable peritoneal metastases is feasible in elderly patients. Updates Surg. 2021;73:719–30.
doi: 10.1007/s13304-020-00966-5
Zambrano-Vera K, Sardi A, Lopez-Ramirez F, Sittig M, Munoz-Zuluaga C, Nieroda C, et al. Outcomes for elderly ovarian cancer patients treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Ann Surg Oncol. 2021;28:4655–66.
doi: 10.1245/s10434-020-09415-4
Tao J, Ji PT, Shen JJ, Lu Y. Survival and complications of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients: a systematic review and meta-analysis. Eur Rev Med Pharm Sci. 2021;25:5330–48.
van de Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goere D, et al. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021;47:2888–92.
doi: 10.1016/j.ejso.2021.05.023
Steele SR, Park GE, Johnson EK, Martin MJ, Stojadinovic A, Maykel JA, et al. The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system. Dis Colon Rectum. 2014;57:303–10.
doi: 10.1097/DCR.0b013e3182a586e7
Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Long-term outcome and prognostic factors of sporadic colorectal cancer in young patients: a large institutional-based retrospective study. Med (Baltim). 2016;95:e3641.
doi: 10.1097/MD.0000000000003641
Hinkle NM, Botta V, Sharpe JP, Dickson P, Deneve J, Munene G. The impact of early recurrence on quality of life after cytoreduction with HIPEC. Am Surg. 2017;83:633–9.
doi: 10.1177/000313481708300630
Goere D, Souadka A, Faron M, Cloutier AS, Viana B, Honore C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64.
doi: 10.1245/s10434-015-4387-5
Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharm. 1999;43(Suppl):S15–25.
doi: 10.1007/s002800051093
Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435–43.
doi: 10.1016/j.ejso.2013.09.030
Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.
doi: 10.1200/JCO.2011.39.7166
Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.
doi: 10.1245/s10434-010-1039-7
Verwaal VJ, Boot H, Aleman BM, van Tinteren H, Zoetmulder FA. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11:375–9.
doi: 10.1245/ASO.2004.08.014
Bijelic L, Yan TD, Sugarbaker PH. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2007;14:2281–8.
doi: 10.1245/s10434-007-9410-z
van Oudheusden TR, Nienhuijs SW, Luyer MD, Nieuwenhuijzen GA, Lemmens VE, Rutten HJ, et al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review. Eur J Surg Oncol. 2015;41:1269–77.
doi: 10.1016/j.ejso.2015.05.018
Leimkuhler M, Hentzen J, Hemmer PHJ, Been LB, van Ginkel RJ, Kruijff S, et al. Systematic review of factors affecting quality of life after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2020;27:3973–83.
doi: 10.1245/s10434-020-08379-9
Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteom Bioinforma. 2017;15:59–72.
doi: 10.1016/j.gpb.2016.12.004
Heidrich I, Ackar L, Mossahebi Mohammadi P, Pantel K. Liquid biopsies: potential and challenges. Int J Cancer. 2021;148:528–45.
doi: 10.1002/ijc.33217
Delli Pizzi A, Chiarelli AM, Chiacchiaretta P, d’Annibale M, Croce P, Rosa C, et al. MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal cancer. Sci Rep. 2021;11:5379.
doi: 10.1038/s41598-021-84816-3
Boland PA, Kelly ME. Advanced colorectal cancer: redefining the outcome paradigm; balancing cure with quality of life. Colorectal Dis. 2021;24:155–6.
Ribas Y, Hotouras A, Wexner SD, D’Hoore A. Shared decision-making and informed consent process in rectal cancer treatment: weighing up oncological and functional outcomes. Colorectal Dis. 2016;18:9–12.
doi: 10.1111/codi.13238
Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, et al. HIPEC methodology and regimens: the need for an expert consensus. Ann Surg Oncol. 2021;28:9098–113.
doi: 10.1245/s10434-021-10193-w
Jastrzebski T, Goscinski M. HIPEC in complementary treatment to cytoreductive procedures: an unexplained issue After the PRODIGE 7 Trial. Ann Surg Oncol. 2021;28:803–5.
doi: 10.1245/s10434-021-10905-2
Sugarbaker PH, Van der Speeten K. The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. J Gastrointest Oncol. 2021;12:S129–S30.
doi: 10.21037/jgo-2020-15